Exciting news in the realm of healthcare, research, academic and Pharmaceutical organizations also!

The Indian Council of Medical Research (ICMR) has launched “India’s first Diabetes Biobank” in Chennai, in collaboration with the Madras Diabetes Research Foundation (MDRF). This groundbreaking initiative aims to combat the rising diabetes epidemic, which currently affects over 10 crore individuals in India.

Extensive Sample Collection – The ICMR-INDIAB study, conducted over 12 years (2008–2020), surveyed over 1.2 lakh individuals across all states and Union Territories of India. This extensive data collection provides a diverse range of biological samples, including blood and DNA, which are now housed in the biobank

Key Highlights:

Comprehensive Repository: The biobank will collect, process, store, and distribute biological samples, including blood and DNA, from significant studies like the ICMR-INDIAB Study and the Registry of Young-Onset Diabetes.

Research Implications: This facility is set to revolutionize diabetes research by enabling advanced studies on disease causes, variations, and complications. Dr. V. Mohan, Chairman of MDRF, stated that this biobank could lead to the identification of novel biomarkers for early diagnosis and personalized treatment strategies.

Longitudinal Studies: The biobank supports long-term research to track diabetes progression and its complications over time, providing critical insights for better management and prevention strategies.

Global Collaboration: By fostering partnerships with researchers and institutions globally, this initiative positions India as a leader in biomedical research.

This milestone not only addresses urgent health challenges but also lays the groundwork for a healthier future through data-driven healthcare innovations. Let’s support this initiative as it paves the way for improved diabetes care in India and contributes to global health research!

DiabetesBiobank #ICMR #MDRF #HealthcareInnovation #DiabetesResearch #HealthEconomics #OutcomesResearch #RealWorldEvidence #CostEffectiveness #Pharmacoeconomics #PatientOutcomes #HealthcarePolicy #ValueBasedHealthcare #EconomicModeling #QualityAdjustedLifeYears #QALYs #EvidenceBasedMedicine #PharmaceuticalInnovation #ClinicalTrials #DrugDevelopment

RegulatoryAffairs

Regards ,
JAKSTAR PHARMA